UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Company as Specified in Charter)
|
| |||
(State or Other Jurisdiction | (Commission | (IRS Employer | ||
of Incorporation) | File Number) | Identification No.) |
| |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting on June 17, 2025 (the “Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below. As of the record date of the Annual Meeting, April 21, 2025, there were 79,237,622 shares of the Company’s common stock outstanding. Each share of common stock entitled its holder to one vote per share.
The stockholders of the Company elected three Class III directors, each to hold office until the Company’s 2028 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows:
Director | For | Withheld | Broker Non-Votes |
Allan Jacobson, Ph.D. | 60,386,986 | 2,122,262 | 4,966,822 |
David P. Southwell | 59,200,375 | 3,308,873 | 4,966,822 |
Alethia Young | 54,894,657 | 7,614,591 | 4,966,822 |
The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified by the Company’s stockholders with 67,259,475 votes “For,” 195,233 votes “Against,” and 21,362 votes “Abstained.”
The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 60,479,157 votes “For,” 1,979,310 votes “Against,” 44,711 votes “Abstained,” and 4,966,822 broker non-votes.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
PTC Therapeutics, Inc. | ||
Date: June 17, 2025 | By: | /s/ Pierre Gravier |
Name: | Pierre Gravier | |
Title: | Chief Financial Officer | |